Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from discontinued operations attributable to Valeant: 0
Today's EPS Names:
RCBC, GASS, YSG, More
Financial Fact:
Income from discontinued operations attributable to Valeant: 0
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Snowflake (SNOW) Tops Q2 EPS by 17c, Offers Guidance
- Hewlett Packard Enterprise (HPE) Tops Q3 EPS by 19c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
